Vistagen Therapeutics (VTGN) EBIT (QoQ) (2011 - 2026)
Vistagen Therapeutics (VTGN) EBIT (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - |
| 10 | Vistagen Therapeutics | 10.41 Mn | 10.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.47% |
| Dec 31, 2025 | 2.53% |
| Sep 30, 2025 | -26.89% |
| Jun 30, 2025 | -9.03% |
| Mar 31, 2025 | 4.13% |
| Dec 31, 2024 | -6.28% |
| Sep 30, 2024 | -17.28% |
| Jun 30, 2024 | -6.80% |
| Mar 31, 2024 | -44.08% |
| Dec 31, 2023 | -16.28% |
| Sep 30, 2023 | 3.12% |
| Jun 30, 2023 | 42.82% |
| Mar 31, 2023 | -25.32% |
| Dec 31, 2022 | 44.16% |
| Sep 30, 2022 | 11.55% |
| Jun 30, 2022 | -18.45% |
| Mar 31, 2022 | -58.39% |
| Dec 31, 2021 | 17.66% |
| Sep 30, 2021 | -65.23% |
| Jun 30, 2021 | -24.57% |